Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note published on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

NASDAQ CYCC opened at $0.30 on Friday. The company has a market cap of $1.89 million, a price-to-earnings ratio of -0.03 and a beta of 0.28. The stock’s fifty day moving average price is $0.33 and its 200 day moving average price is $0.53. Cyclacel Pharmaceuticals has a 1 year low of $0.29 and a 1 year high of $4.00.

Insider Activity

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of Cyclacel Pharmaceuticals stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total transaction of $5,838,864.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 23.97% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.